Full video transcriptClick to expand
Auto-generated transcript of @drdondiego's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00CNN published an article that has a lot of people concerned.
- 0:03This article shares the experiences of a couple of people who are diagnosed with
- 0:06stomach paralysis, the medical term being gastroparesis, after taking GLP1 medications like Ozempic and
- 0:12wigobi. I'm not going to comment on these individuals medical experiences because I do not know their
- 0:18medical history and I am not their doctor but I do want to talk about gastroparesis in general.
- 0:23Gastroparesis is a serious medical condition where the stomach is emptying more slowly into the small
- 0:27intestine and as a result of that there can be symptoms like nausea, vomiting and abdominal pain.
- 0:33And yes this sounds like a lot of the side effects that we see those taking GLP1 medications
- 0:37experience. The diagnosis of gastroparesis requires two things. There must be objective evidence of
- 0:43delayed gastric emptying and this is measured by a gastric emptying scan. So we will actually watch
- 0:49how slowly your stomach is emptying and see that there is a delay. Diagnosis also requires that
- 0:54someone have the typical symptoms such as nausea, vomiting and abdominal pain. Gastroparesis, the
- 0:59condition is something that is distressing to patients. So there must be the positive testing
- 1:04and the symptoms to have this diagnosis. And I want to stress here if somebody is having such
- 1:09severe symptoms taking a GLP1 medication it is so important to stay in contact with their physician
- 1:15because most of us are not going to keep patients who are in severe distress on medications that can
- 1:21make that worse. There are a couple points that I'd like to mention when talking about gastroparesis.
- 1:26With people in general and with different types of foods the pattern and the rate of
- 1:30stomach emptying can vary considerably. And also in studies of those with gastroparesis the gastric
- 1:36emptying time did not necessarily correlate with disease severity. Many medications including GLP1
- 1:43medications can be a potential cause of gastroparesis but typically with a medication induced
- 1:49gastroparesis we would see the symptoms resolve upon discontinuation of the medication. In the majority
- 1:55of patients GLP1 medications are well tolerated and cause a therapeutic delayed gastric emptying
- 2:00but not gastroparesis.
GLP-1 drugs and gastroparesis: separating real risk from TikTok panic
Quick answer
GLP-1 receptor agonists including semaglutide slow gastric emptying as part of their intended mechanism, which complicates the diagnosis of true medication-induced gastroparesis. The diagnostic standard requires both a positive gastric emptying scintigraphy result and symptomatic distress, and clinicians should monitor patients closely if gastrointestinal symptoms are severe or not resolving. The 2023 Sodhi et al. JAMA study found a statistically significant increased risk of gastroparesis in GLP-1 users compared to controls, though absolute risk remained low, and the reversibility of this effect after discontinuation is not fully established.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and gastroparesis: separating real risk from TikTok panic, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs and gastroparesis: separating real risk from TikTok panic" from Doctor DonDiego 🆘🇺🇸. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists including semaglutide slow gastric emptying as part of their intended mechanism, which complicates the diagnosis of true medication-induced gastroparesis.
The reason this review is not generic is the source wording and the canonical claim label "glp1 duet with dr jennah weightdoc ozempic stomach paralysis glp1." In this clip, the useful excerpt is: "CNN published an article that has a lot of people concerned." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists including semaglutide slow gastric emptying as part of their intended mechanism, which complicates the diagnosis of true medication-induced gastroparesis.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists including semaglutide slow gastric emptying as part of their intended mechanism, which complicates the diagnosis of true medication-induced gastroparesis. The diagnostic standard requires both a positive gastric emptying scintigraphy result and symptomatic distress, and clinicians should monitor patients closely if gastrointestinal symptoms are severe or not resolving. The 2023 Sodhi et al. JAMA study found a statistically significant increased risk of gastroparesis in GLP-1 users compared to controls, though absolute risk remained low, and the reversibility of this effect after discontinuation is not fully established.
- A 2023 JAMA study (Sodhi et al.) found GLP-1 users had roughly 3-4 times higher risk of a gastroparesis diagnosis versus a weight-loss medication control group, but absolute risk was still low.
- Gastroparesis cannot be diagnosed by symptoms alone. A gastric emptying scan showing delayed emptying is required along with clinical symptoms, per ACG guidelines.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- A 2023 JAMA study (Sodhi et al.) found GLP-1 users had roughly 3-4 times higher risk of a gastroparesis diagnosis versus a weight-loss medication control group, but absolute risk was still low.
- Gastroparesis cannot be diagnosed by symptoms alone. A gastric emptying scan showing delayed emptying is required along with clinical symptoms, per ACG guidelines.
- GLP-1 medications slow gastric emptying by design. That physiological effect is part of how they work and is not the same as gastroparesis, though it can look similar on testing.
- Nausea rates in GLP-1 trials like SUSTAIN-6 reached up to 44%, meaning GI side effects are common and expected, but severe or persistent symptoms still warrant clinical evaluation.
- If medication-induced gastroparesis is the cause, symptoms are expected to improve after stopping the drug, though long-term follow-up data for GLP-1-specific cases remain limited.
- Patients should not self-manage severe GI symptoms on GLP-1 medications. Staying in contact with a prescribing clinician is necessary to distinguish expected effects from a serious adverse event.
- The gastric emptying delay seen with GLP-1 medications can produce false-positive findings on scans if testing is done while a patient is still on the drug, complicating diagnosis.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drdondiego actually say?
Dr. Dondiego responded to a CNN article about GLP-1 users developing gastroparesis, and he was careful not to overreach. His core argument: gastroparesis requires both objective evidence of delayed gastric emptying on a gastric emptying scan AND symptomatic distress. He drew a line between "therapeutic delayed gastric emptying" caused by GLP-1s and actual gastroparesis, and he noted that medication-induced gastroparesis typically resolves when the drug is stopped. He also pushed patients with severe symptoms to stay in contact with their doctor. For a TikTok duet responding to a CNN scare piece, that's a measured, clinically grounded take.
Does the science back this up?
Yes, mostly. The diagnostic criteria he cited are accurate. Gastroparesis requires documented delayed gastric emptying, usually via a standardized four-hour scintigraphy study, plus symptoms. That is consistent with the American College of Gastroenterology guidelines (Camilleri et al., 2013, American Journal of Gastroenterology). His point about GLP-1 medications slowing gastric emptying as a feature, not just a bug, is also well-supported. Semaglutide delays gastric emptying as part of its mechanism, reducing post-meal glucose spikes (Nauck et al., 2011, Diabetes, Obesity and Metabolism). The complication is distinguishing that expected physiological effect from pathological gastroparesis, which is genuinely difficult in clinical practice and something he only partially addressed.
- GLP-1 receptor agonists slow gastric emptying through vagal pathways and direct gastric effects.
- A 2023 JAMA study (Sodhi et al., 2023, JAMA) found GLP-1 users had a higher risk of gastroparesis diagnosis compared to bupropion-naltrexone users, though absolute risk remained low.
- The same study found increased rates of pancreatitis and bowel obstruction, which he did not mention.
What did they get wrong (or right)?
He got the diagnostic framework right, and his clinical instinct to tell patients not to white-knuckle severe symptoms is sound. The claim that "in the majority of patients GLP-1 medications are well tolerated" is accurate based on trial data, though "well tolerated" in clinical trials still includes substantial nausea rates, up to 44% in SUSTAIN-6 (Marso et al., 2016, New England Journal of Medicine).
Where he was incomplete: he said medication-induced gastroparesis "typically" resolves on discontinuation. That is probably true but the evidence base for full reversal is limited. The 2023 Sodhi JAMA study raised questions about whether some GLP-1-associated gastroparesis persists. He also did not mention that the gastric emptying scan findings in GLP-1 users can look like gastroparesis even without clinical disease, which creates real diagnostic confusion that clinicians are still working through.
What should you actually know?
The CNN story that prompted this video was not fabricated, but it was anecdotal. Case reports and news stories about gastroparesis in GLP-1 users reflect a real signal that researchers are taking seriously. The Sodhi et al. 2023 JAMA study, which is the most cited evidence on this, found a roughly 3-4 times higher risk of gastroparesis diagnosis in GLP-1 users compared to a weight-loss medication control group. That sounds alarming until you see the absolute numbers: still a rare outcome in a large population.
What matters clinically is that patients should not ignore persistent severe nausea, vomiting, or abdominal pain on these medications. Those symptoms can reflect the drug doing its job, or they can be a signal of something going wrong. That distinction requires a real clinical conversation, not a TikTok comment, and Dr. Dondiego said exactly that. Credit where it is due.
- Do not self-diagnose gastroparesis based on GLP-1 side effects alone.
- A formal gastric emptying scan is required for diagnosis, not symptoms alone.
- If symptoms are severe or persistent, contact your prescribing clinician before stopping the medication on your own.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Doctor DonDiego 🆘🇺🇸 · TikTok creator
5.8K views on this video
#duet with @Dr Jennah | WeightDoc Ozempic & stomach paralysis 😱🫣 #glp1community #obesitydoctor #sequenceclinician
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about a 2023 jama study (sodhi et al.) found glp-1 users?
A 2023 JAMA study (Sodhi et al.) found GLP-1 users had roughly 3-4 times higher risk of a gastroparesis diagnosis versus a weight-loss medication control group, but absolute risk was still low.
What does the video say about gastroparesis cannot be diagnosed by symptoms alone. a gastric emptying?
Gastroparesis cannot be diagnosed by symptoms alone. A gastric emptying scan showing delayed emptying is required along with clinical symptoms, per ACG guidelines.
What does the video say about glp-1 medications slow gastric emptying by design. that physiological effect?
GLP-1 medications slow gastric emptying by design. That physiological effect is part of how they work and is not the same as gastroparesis, though it can look similar on testing.
What does the video say about nausea rates in glp-1 trials like sustain-6 reached up to?
Nausea rates in GLP-1 trials like SUSTAIN-6 reached up to 44%, meaning GI side effects are common and expected, but severe or persistent symptoms still warrant clinical evaluation.
What does the video say about if medication-induced gastroparesis?
If medication-induced gastroparesis is the cause, symptoms are expected to improve after stopping the drug, though long-term follow-up data for GLP-1-specific cases remain limited.
What does the video say about patients should not self-manage severe gi symptoms on glp-1 medications.?
Patients should not self-manage severe GI symptoms on GLP-1 medications. Staying in contact with a prescribing clinician is necessary to distinguish expected effects from a serious adverse event.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Doctor DonDiego 🆘🇺🇸, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.